		<div class="wpcnt">
			<div class="wpa">
				<span class="wpa-about">Advertisements</span>
				<div class="u top_amp">
							<amp-ad width="300" height="265"
		 type="pubmine"
		 data-siteid="111265417"
		 data-section="2">
		</amp-ad>
				</div>
			</div>
		</div><p>A drug that frees the immune system to attack a devastating form of lung cancer has been shown to double the life expectancy of genetically targeted patients.</p>
<p>Nivolumab is one of new generation of immunotherapy drugs that release cancer-applied brakes on the immune system called “checkpoints”.</p>
<p>The results, from a major international trial involving patients who had already been treated for the most common form of lung cancer, were described by one expert as a “paradigm shift”.</p>
<p>In the Phase III trial, the last step before a drug is licensed for use in clinics, researchers compared the effectiveness of nivolumab and the standard chemotherapy drug docetaxel in 582 patients with advanced non-squamous non-small cell lung cancer (NSCLC).</p>
<p>The disease accounts for around 85% of all cases of lung cancer, which is diagnosed in 43,463 new patients and causes 35,371 deaths each year in the UK.</p>
<p><a href="http://londonglossy.com/wp-content/uploads/2015/06/image1.jpg"><img src="http://londonglossy.com/wp-content/uploads/2015/06/image1.jpg" alt="Cancer" width="600" height="602" class="aligncenter size-full wp-image-75036" /></a></p>
<p>Overall, nivolumab reduced the risk of dying by 27% compared with docetaxel and increased typical survival time from 9.4 to 12.2 months.</p>
<p>But the drug was found to be most effective in patients whose cancers produced higher levels of a tumour protein called PD-L1, potentially paving the way to personalised treatments.</p>
<p>For those with the most active PD-L1 gene in their cancer cells survival time more than doubled from eight to 19.4 months.</p>
<p>Lower “expression levels” led to life extensions of 10 months and eight months as amounts of the molecule reduced, while patients with little or no PD-L1 saw no survival benefit. Almost 80% of patients had measurable levels of the protein.</p>
			<div style="padding-bottom:15px;" class="wordads-tag" data-slot-type="belowpost">
				<div id="atatags-dynamic-belowpost-68cd1cbba776b">
					<script type="text/javascript">
						window.getAdSnippetCallback = function () {
							if ( false === ( window.isWatlV1 ?? false ) ) {
								// Use Aditude scripts.
								window.tudeMappings = window.tudeMappings || [];
								window.tudeMappings.push( {
									divId: 'atatags-dynamic-belowpost-68cd1cbba776b',
									format: 'belowpost',
								} );
							}
						}

						if ( document.readyState === 'loading' ) {
							document.addEventListener( 'DOMContentLoaded', window.getAdSnippetCallback );
						} else {
							window.getAdSnippetCallback();
						}
					</script>
				</div>
			</div>
Discover more from London Glossy Post
Subscribe to get the latest posts sent to your email.
